Haemonetics Corporation (HAE)
Thursday, November 5, 2026
Key stats
Chart
Price, buy and sell signals and key levels on one chart.
Past 1Y
MA21MA180
SignalsBuyEarly buySellEarly sellTurning pointsSwing highSwing low
Up dayDown day
Thursday, November 5, 2026
Price, buy and sell signals and key levels on one chart.
Haemonetics (HAE) closed at $105.79 on Sep 28, 2026, up 0.5% on the day. The stock is up 0.8% over the past month, up 40.8% over three months, up 32.0% year to date and up 119.6% over the past year (since Sep 26, 2025). It trades 4.2% below its 52-week high of $110.45 and 107.4% above its 52-week low of $51.00. The close sits above its 50-day moving average ($96.71) and above its 200-day moving average ($74.60).
HAE is scheduled to report earnings on Nov 5, 2026, before market open. Over its last 8 reports the stock moved an average of 11.7% on the first trading day after earnings, beating the options-implied move in 4 of 8.
Haemonetics is scheduled to report on Nov 5, 2026, before market open.
Over the last 8 reports, HAE moved an average of 11.7% on the first trading day after earnings. The move beat the options-implied move in 4 of 8 reports.
Yes — the Sep 28, 2026 close of $105.79 is 41.8% above the 200-day average of $74.60.
HAE closed 4.2% below its 52-week high of $110.45.
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.